Fizocare operates as an independent brand with full ownership of its product designs, quality systems, and customer relationships. Governance is not a bureaucratic overlay—it is the framework that ensures every strategic decision, from product architecture to market entry, serves one fixed reference point: patient safety and clinical efficacy. Since its founding in 2014, Fizocare has maintained a lean but rigorous governance structure. Shareholders appoint a Board of Directors responsible for strategic oversight. The Board brings together expertise in rehabilitation medicine, physiotherapy, biomedical engineering, occupational therapy, speech-language therapy, dermatology, and global regulatory affairs—ensuring that product decisions are grounded in clinical reality, not commercial convenience.
Specialised committees operate within the Board, proportionate to the company’s scale:
The Board appoints executive officers to carry out the strategic vision. Internal groups support them, including a Clinical Outcomes & Technology Committee that reviews equipment performance, treatment efficacy data, adverse event reports, and field correction notices, and a Risk & Compliance Panel that manages regulatory changes, supplier audits, and field corrections. An independent Internal Audit team reports directly to the Audit Committee.
Headquartered in Shenzhen, Fizocare applies these governance principles consistently across all markets. Lean structure does not mean weak governance—it means every decision is visible, every risk is owned, every leader is accessible. Governance is not a chart. It is a covenant with the people who rely on Fizocare systems: patients awaiting functional recovery, physiotherapists delivering every treatment, occupational therapists rebuilding daily living skills, speech-language therapists restoring communication, rehabilitation physicians directing care, dermatologists and aesthetic practitioners enhancing skin health, and clinic administrators managing finite resources.
Fizocare is led by its founding team and an executive management group, with strategic direction reviewed by a Board of Directors. The Board’s primary function is to ensure that long-term strategy—product portfolio, technology roadmaps, market expansion—remains aligned with core values and patient safety. The Board delegates specific oversight to a Clinical Outcomes & Technology Committee, which reviews equipment-related field failures, treatment efficacy complaints, adverse event reports, regulatory inspection findings, and clinical integration safety issues. The committee meets quarterly and reports directly to the full Board. For a company of Fizocare’s size and focus, this ensures that quality and safety never become subordinate to commercial pressure.
Three anchors guide every decision: transparency, accountability, and unwavering prioritisation of patient safety and clinical efficacy. Design reviews, supplier selection, field correction decisions, and post-market surveillance are all documented and auditable. Accountability extends to the physiotherapists, occupational therapists, speech-language therapists, rehabilitation physicians, dermatologists, aesthetic practitioners, and nurses who depend on every shockwave pulse, every electrotherapy waveform, every laser emission, every thermographic assessment.
Fizocare operates under a certified quality management system compliant with ISO 13485—the same standard required of medical device manufacturers worldwide. The risk management process follows ISO 14971, with specific attention to rehabilitation and aesthetic hazards: electrical safety (IEC 60601 for electrotherapy and laser devices), shockwave energy accuracy, laser fluence precision, PEMF field strength consistency, compression pressure reliability, support brace biomechanical integrity, and thermography imaging accuracy. NMPA registration in China, CE marking for select products, and additional regional registrations are maintained directly by Fizocare. Active surveillance of regulatory changes in China, the EU, and other target markets is continuous. Compliance is not a one-time audit—it is daily discipline: document control, training, process adherence.
Because Fizocare vertically integrates its product design and manufacturing resources, the company exercises direct control over supplier qualifications. A rigorous supplier qualification programme includes annual on-site audits, focusing on adherence to ISO 13485 and applicable rehabilitation and aesthetic device standards. No component or assembly enters a Fizocare system without passing internal verification.
We view physiotherapists, occupational therapists, speech-language therapists, rehabilitation physicians, dermatologists, aesthetic practitioners, nurses, clinic administrators, biomedical engineers, distributors, regulators, employees, and manufacturing partners as essential stakeholders. Our engagement takes practical forms: clinical advisory boards during product development, post-deployment surveys sent to every new customer, open communication channels for distributors to report field issues, and regular quality and performance reviews with factory partners. We are not a distant, faceless entity. We are an accessible team, and we listen—because listening is the fastest route to meaningful improvement.
Subscribe to comprehensive rehabilitation and therapeutic solutions from Fiziocare. Elevate patient outcomes across physical therapy, neuro-rehab, and post-operative settings with integrated, science-driven systems.
© Nortek HealthCare Group Ltd., 2009-2026. All rights reserved.
This site operates under the laws of the People's Republic of China. Your access and use constitute acceptance of these Terms of Use and our Privacy Policy. All content is governed by our Privacy Notice. For details or inquiries, please Contact Us or use the site's search function.
